Neovasc Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVCN research report →
Price Chart
About the company
Neovasc Inc. is a specialized medical technology enterprise focused on the development, production, and worldwide distribution of products for the cardiac health sector, with a significant presence across Europe and other international markets. The company's key innovations feature the Tiara system, an advanced transcatheter technology for managing mitral valve disease, and the Neovasc Reducer, which offers a therapeutic option for patients suffering from refractory angina.
- CEO
- Fredericus A. Colen
- IPO
- 2001
- Employees
- 49
- HQ
- Richmond, BC, CA
Get TickerSpark's AI analysis on NVCN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $82.86M
- P/E
- -1.99
- PEG
- 0.04
- P/S
- 21.78
- P/B
- 5.18
- EV/EBITDA
- -1.78
- Div Yield
- 0.00%
- Gross Margin
- 79.66%
- Op Margin
- -886.75%
- Net Margin
- -1082.90%
- ROE
- -121.07%
- ROIC
- -116.83%
Latest fiscal year · YoY change
- Revenue
- $3.81M+49.4%
- Gross Profit
- $3.03M+52.2%
- Op Income
- $-33,740,809
- Net Income
- $-41,204,418-65.6%
- EPS
- $-15.07-52.5%
- OCF Growth
- +8.0%
- FCF Growth
- +8.4%
- 52W High
- $30.07
- 52W Low
- $4.58
- 50D MA
- $29.31
- 200D MA
- $15.47
- Beta
- 2.01
- RSI (14)
- 64
- Avg Volume
- 25.78K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Neovasc reported record quarterly revenue growth and improving reimbursement momentum for the Reducer, while continuing to burn cash and pushing out COSIRA-II enrollment timing.· November 10, 2022
- Revenue rose 31% year over year to $923,000, marking another record quarter.
- Gross margin was 76% versus 77% a year ago, with higher direct sales in Europe expected to support margins over time.
- Reducer reimbursement momentum improved in the U.K., U.S., and Germany, and the company said roughly 80% of revenue now comes from outside the Dutch countries.
- COSIRA-II is advancing but slower than hoped; 48 patients were enrolled and 25 randomized at 16 sites, with completion now expected in the first half of 2024.
- Tiara development has been indefinitely paused as management focuses resources on the Reducer and the U.S./European expansion strategy.
For the quarter ended September 30, 2022, revenue increased 31% year over year to $923,000 from $703,000. Operating loss was $6.7 million, versus $6.7 million a year ago, and comprehensive loss was $8.2 million, versus $6.9 million a year ago; basic and diluted loss per share was $3.00 versus $2.79. Gross margin was 76% compared with 77% in the prior-year period, and cost of goods sold was $220,000 versus $165,000. As of September 30, 2022, cash and cash equivalents were $31.3 million. Management said cash runway is now expected to last into the first half of 2024, due mainly to COSIRA-II administrative expenses and slightly higher everyday operating costs.
Fred Colen framed the quarter as strong operational progress despite currency headwinds, COVID-related procedure disruptions, and staffing constraints in Europe. He emphasized three priorities: expanding Reducer reimbursement and utilization in Europe, advancing COSIRA-II toward U.S. approval, and supporting additional clinical evidence in ANOCA. He also said Tiara has been paused indefinitely so the company can concentrate on the Reducer.
Chris Clark reported revenue of $923,000, up 31%, with gross margin at 76% and cost of goods sold at $220,000. He detailed the quarter’s loss profile: operating loss of $6.7 million, comprehensive loss of $8.2 million, and $3.00 basic and diluted loss per share. He also said cash and cash equivalents were $31.3 million at quarter-end and that runway is now expected into the first half of 2024, citing COSIRA-II administrative expenses and higher-than-expected routine operating expenses.
Analysts focused mainly on COSIRA-II execution and reimbursement. David Martin asked about the gap between enrollment and randomization, the pace of site activation, the U.S. versus Canada site split, and whether Germany’s full reimbursement decision was still due this month. Fred Colen said the enrollment-to-randomization lag is typically several weeks and varies by site experience, all activated sites so far are in the U.S., and Germany’s first reimbursement response was positive but a final decision is not expected until later in 2023.
The bull case from this call is that Neovasc is seeing real commercial traction for the Reducer, with record revenue, improved reimbursement coverage, and a more diversified European revenue base. Management also highlighted CMS outpatient reimbursement effective January 1, 2023, plus early positive ANOCA data and a potentially broader patient pool.
The main risks are execution and timing: COSIRA-II enrollment is slower than hoped, with only 48 enrolled and 25 randomized at 16 sites, and the company pushed completion to the first half of 2024. Revenue remains small and exposed to currency weakness, COVID/staffing disruptions in Europe, and ongoing losses, while Tiara has been put on hold indefinitely.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 0.0%
- Shares Outstanding
- 2.76M
- Float Shares
- 0
of shares held by institutions
20 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Usca Ria LLC | 300.00K | ▲ 156.00K |
Our NVCN coverage
Recent articles, reports, and earnings notes.
No research on NVCN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NVCN report →Shockwave Medical, Inc. Completes Acquisition of Neovasc
globenewswire.com · Apr 11
Shockwave Medical Completes Acquisition of Neovasc
globenewswire.com · Apr 11
Neovasc Announces Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update
globenewswire.com · Mar 31
Neovasc Shareholders Approve Acquisition by Shockwave Medical
newsfilecorp.com · Mar 6
A Bull Market Is Coming: 1 Outstanding Growth Stock Down 36% to Buy and Hold
fool.com · Feb 22
Neovasc Announces German Reimbursement Renewal
newsfilecorp.com · Feb 1
Mergers and Acquisitions in 2023 Off To A Strong Start
marketbeat.com · Jan 27
Shockwave Medical To Buy Neovasc: Details (NVCN)
pulse2.com · Jan 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.